Plain-English translation of NCT07284758 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Multiple Myeloma research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This is a Phase 2 trial testing plus — a new two-drug combination — in people with multiple myeloma that has come back or stopped responding to earlier treatments. Researchers want to see how well this medication works, how safe it is, and what side effects people experience. The study will include about 100 participants across multiple medical centers.
Multiple myeloma is a serious blood cancer, and some patients develop resistance to standard treatments, leaving them with limited options. This trial is exploring whether this new drug combination can help people whose cancer has become hard to treat, potentially offering hope to those who have exhausted other therapies.
You likely qualify if…
You likely don't qualify if…
You would take the medication by mouth in 28-day treatment cycles and continue as long as the treatment is working and you are tolerating it well. You will have regular visits to your study site for blood tests, health monitoring, and check-ins with the medical team to see how you are responding and watch for any side effects. The study will track how well the medication works for your cancer and carefully monitor your safety throughout your participation.
AI-generated summary from trial data · Aug 9, 2026 · Not medical advice
United States